Immucell Value Stock - Dividend - Research Selection
Immucell
ISIN: US4525253062 , WKN: 885825
Market price date:
Market price:
Market price:
Fundamental data and company key figures of the share
| Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | |||||||||||||||||||||||||||||||||||||||||||||||||
Do you want to do make a detailed fundamental analysis of this stock?
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | |
| Market Capitalization | USD |
| Country | |
| Indices | |
| Sectors | |
| Raw Data Source | |
| Stock Split | |
| Internet |
Description of the company
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,
NEWS
ImmuCell Full Year 2022 Earnings: US$0.32 loss per share (vs US$0.01 loss in FY 2021)
2023-02-23
ImmuCell ( NASDAQ:ICCC ) Full Year 2022 Results Key Financial Results Revenue: US$18.6m (down 3.5% from FY 2021). Net...
ImmuCell Corporation (ICCC) Q4 2022 Earnings Call Transcript
2023-02-22
ImmuCell Corporation (NASDAQ:NASDAQ:ICCC) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ETCompany ParticipantsJoe Diaz - Lytham Partners, IRMichael Brigham - President and...
ImmuCell Corporation 2022 Q4 - Results - Earnings Call Presentation
2023-02-22
The following slide deck was published by ImmuCell Corporation in conjunction with their 2022 Q4 earnings call.
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022
2023-02-21
PORTLAND, Maine, Feb. 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the year ended December 31, 2022. Management’s Discussion:“Our unaudited, preliminary product sales were first reported on January 9, 2023,” comme
ImmuCell GAAP EPS of -$0.32, revenue of $18.57M
2023-02-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
2023-02-15
Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ETPORTLAND, Maine, Feb. 15, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the year ended December 31, 2022 after the market closes on Tuesday, Februar
ImmuCell trading resumes
2023-01-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
ImmuCell trading halted, volatility trading pause
2023-01-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022
2023-01-09
PORTLAND, Maine, Jan. 09, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the year ended December 31, 2022. Preliminary, Unaudited Total Sales Results: 2022 2021 ($ Decrease) (% Decrease) During the Three-Month Peri
Fly Intel: After-Hours Movers
2023-01-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.